Objectives: The therapeutic arsenal for MRSA infections is limited. The aim of this study was to assess the non-inferiority of a combination of trimethoprim/sulfamethoxazole plus rifampicin versus linezolid alone for the treatment of MRSA infection.
Methods: We conducted a randomized, open-label, single-centre, non-inferiority trial comparing trimethoprim/sulfamethoxazole (160 mg/800 mg three times daily) plus rifampicin (600 mg once a day) versus linezolid (600 mg twice a day) alone in adult patients with various types of MRSA infection. Patients were allocated 1:1 to either regimen. The primary outcome was clinical cure at 6 weeks after the end of treatment (non-inferiority margin 20%) assessed by both ITT and PP analyses. Secondary outcomes included the microbiologically documented persistence of MRSA in clinical cultures, mortality and adverse events. The study protocol has been registered with ClinicalTrials.gov (NCT00711854).
Results: Overall, 150 patients were randomized to one of the two treatment arms between January 2009 and December 2013 and were included in the ITT analysis. Of these 56/75 (74.7%) in the linezolid group and 59/75 (78.7%) in the trimethoprim/sulfamethoxazole and rifampicin group experienced clinical success (risk difference 4%, 95% CI -9.7% to 17.6%). The results were confirmed by the PP analysis, with 54/66 (81.8%) cured patients in the linezolid group versus 52/59 (88.1%) in the trimethoprim/sulfamethoxazole and rifampicin group (risk difference 6.3%, 95% CI -6.8% to 19.2%). There were no statistically significant differences between the two groups in any of the secondary outcomes, including microbiologically documented failure. Four adverse drug reactions attributed to the study medication occurred in the linezolid group versus nine in the trimethoprim/sulfamethoxazole and rifampicin group.
Conclusions: Compared with linezolid, trimethoprim/sulfamethoxazole and rifampicin seems to be non-inferior in the treatment of MRSA infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dku352 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serotype distribution and antimicrobial susceptibility of Streptococcus suis isolates from porcine diagnostic samples in Hungary, 2020-2023.
Porcine Health Manag
January 2025
Department of Pathology, University of Veterinary Medicine Budapest, Üllő, Hungary.
Background: Streptococcus suis (S. suis) is a major swine pathogen and a significant zoonotic agent, causing substantial economic losses in the swine sector and having considerable public health importance. The control and management of S.
View Article and Find Full Text PDFAntimicrobial Susceptibility Patterns and Antimicrobial Therapy of Infections Caused by Species.
Medicina (Kaunas)
December 2024
Department of Internal medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
: species have become significant sources of infections acquired in hospital settings and are commonly linked to high mortality rates. Antimicrobial resistance can be influenced by species, geographical location, antimicrobial susceptibility testing methods, and the time of bacterial isolation. There are distinct antimicrobial susceptibility patterns among species, and the investigation into potential antibiotic susceptibility variations among species is beneficial.
View Article and Find Full Text PDFPrevalence and Antimicrobial Resistance Trends among Lower Respiratory Tract Pathogens in Crete, Greece, 2017-2022.
Infect Chemother
December 2024
Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece.
Background: Lower respiratory tract infections (LRTIs) are the most common infections in humans accounting for significant morbidity and mortality. Management of LRTIs is complicated due to increasing antimicrobial resistance. This study investigated the prevalence and trends of antimicrobial resistance for bacteria isolated from respiratory samples of patients with LRTIs.
View Article and Find Full Text PDFChanges in population genetic structure of serotype 19A Streptococcus pneumoniae after universal childhood use of the 10-valent pneumococcal conjugate vaccine in Brazil.
Vaccine
December 2024
Instituto Biomédico, Universidade Federal Fluminense, Alameda Barros Terra, s/n, São Domingos, Niterói, RJ 24020-150, Brazil. Electronic address:
Article Synopsis
- The introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) in Brazil has significantly decreased the prevalence of vaccine serotype-related invasive pneumococcal disease (IPD) in children, but non-vaccine serotypes, particularly 19A, have become more prominent.
- The study analyzed 32 serotype 19A isolates from a variety of patients, finding that the majority of these isolates came from children and displayed high levels of non-susceptibility to commonly used antibiotics.
- A significant number of the isolates were multidrug resistant, with a notable shift in genetic lineages, indicating evolving resistance patterns following the introduction of PCV10.
[Etiological characteristics of in Henan Province, 2013-2022].
Zhonghua Liu Xing Bing Xue Za Zhi
November 2024
Institute of Infectious Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou450016, China.
To analyze the genus, drug resistance/virulence and phylogenetic characteristics of strains isolated from brucellosis surveillance sentinels in Henan Province from 2013 to 2022, and provide baseline data for the surveillance, early warning and outbreak tracing of brucellosis. Blood samples were collected from patients with infection for strain isolation, culture and species identification, drug susceptibility test, whole genome sequencing, splicing and assembly, functional/virulence/resistance gene prediction analysis and phylogenetic tree drawing based on single nucleotide polymorphism (SNP). In 36 brucellosis patients, the majority were men (86.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!